DK174866B1 - Anvenelse af væksthormonudløsende faktor ved fremstilling af et præparat til diagnose af Alzheimer - Google Patents

Anvenelse af væksthormonudløsende faktor ved fremstilling af et præparat til diagnose af Alzheimer Download PDF

Info

Publication number: DK174866B1
Authority: DK; Denmark
Prior art keywords: growth hormone; alzheimer; disease; composition; triggering factor
Prior art date: 1988-01-26

Application number

DK198900314A

Other languages

Danish (da)

English (en)

Other versions

DK31489D0 (da

DK31489A (da

Inventor

Ramon Cacabelos

Francisco Rubia Vila

Thomas Ortiz Alonso

Original Assignee

Applied Research Systems

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-01-26

Filing date

1989-01-25

Publication date

2004-01-05

1988-01-26 Priority claimed from US07/148,667 external-priority patent/US4939124A/en

1989-01-25 Application filed by Applied Research Systems filed Critical Applied Research Systems

1989-01-25 Publication of DK31489D0 publication Critical patent/DK31489D0/da

1989-07-27 Publication of DK31489A publication Critical patent/DK31489A/da

2004-01-05 Application granted granted Critical

2004-01-05 Publication of DK174866B1 publication Critical patent/DK174866B1/da

Links

208000024827 Alzheimer disease Diseases 0.000 title claims description 15
239000000203 mixture Substances 0.000 title claims description 7
238000003745 diagnosis Methods 0.000 title claims description 6
230000006870 function Effects 0.000 claims abstract description 6
230000003340 mental effect Effects 0.000 claims abstract description 6
230000004044 response Effects 0.000 claims description 10
206010039966 Senile dementia Diseases 0.000 claims description 9
239000012634 fragment Substances 0.000 claims description 4
102000018997 Growth Hormone Human genes 0.000 claims description 3
108010051696 Growth Hormone Proteins 0.000 claims description 3
239000000122 growth hormone Substances 0.000 claims description 3
238000001990 intravenous administration Methods 0.000 claims description 2
230000002708 enhancing effect Effects 0.000 claims 1
238000007920 subcutaneous administration Methods 0.000 claims 1
229940088597 hormone Drugs 0.000 abstract description 7
239000005556 hormone Substances 0.000 abstract description 7
230000002267 hypothalamic effect Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
101100424823 Arabidopsis thaliana TDT gene Proteins 0.000 description 11
201000010099 disease Diseases 0.000 description 9
102000005157 Somatostatin Human genes 0.000 description 8
108010056088 Somatostatin Proteins 0.000 description 8
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 8
229960000553 somatostatin Drugs 0.000 description 8
206010012289 Dementia Diseases 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000012360 testing method Methods 0.000 description 6
230000000694 effects Effects 0.000 description 5
230000006399 behavior Effects 0.000 description 4
210000003169 central nervous system Anatomy 0.000 description 4
238000011835 investigation Methods 0.000 description 3
208000017701 Endocrine disease Diseases 0.000 description 2
230000002159 abnormal effect Effects 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000037396 body weight Effects 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000960 hypophysis hormone Substances 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000006742 locomotor activity Effects 0.000 description 2
230000001730 monoaminergic effect Effects 0.000 description 2
230000001722 neurochemical effect Effects 0.000 description 2
230000000955 neuroendocrine Effects 0.000 description 2
230000002263 peptidergic effect Effects 0.000 description 2
208000020016 psychiatric disease Diseases 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
230000003997 social interaction Effects 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
208000000044 Amnesia Diseases 0.000 description 1
241000557626 Corvus corax Species 0.000 description 1
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
108090000189 Neuropeptides Proteins 0.000 description 1
241000700159 Rattus Species 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000036528 appetite Effects 0.000 description 1
235000019789 appetite Nutrition 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
230000003925 brain function Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000001713 cholinergic effect Effects 0.000 description 1
230000001149 cognitive effect Effects 0.000 description 1
230000006998 cognitive state Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
230000001054 cortical effect Effects 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
210000003100 hypothalamo-hypophyseal system Anatomy 0.000 description 1
210000003016 hypothalamus Anatomy 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100000863 loss of memory Toxicity 0.000 description 1
238000013507 mapping Methods 0.000 description 1
239000003550 marker Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000000034 method Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
230000036651 mood Effects 0.000 description 1
210000001577 neostriatum Anatomy 0.000 description 1
210000000607 neurosecretory system Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000005471 regulation of growth hormone secretion Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000033764 rhythmic process Effects 0.000 description 1
201000000980 schizophrenia Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000006403 short-term memory Effects 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B1/00—Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Endocrinology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurosurgery (AREA)
Surgery (AREA)
Neurology (AREA)
Medical Informatics (AREA)
Psychiatry (AREA)
Chemical Kinetics & Catalysis (AREA)
Hospice & Palliative Care (AREA)
Physics & Mathematics (AREA)
Biophysics (AREA)
Optics & Photonics (AREA)
Pathology (AREA)
Radiology & Medical Imaging (AREA)
General Chemical & Material Sciences (AREA)
Heart & Thoracic Surgery (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Investigating Or Analysing Biological Materials (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

DK198900314A 1988-01-26 1989-01-25 Anvenelse af væksthormonudløsende faktor ved fremstilling af et præparat til diagnose af Alzheimer DK174866B1 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US14866788		1988-01-26
US07/148,667 US4939124A (en)	1988-01-26	1988-01-26	Treatment and diagnosis of dementia
US20610088		1988-06-13
US07/206,100 US5089472A (en)	1988-01-26	1988-06-13	Use of growth hormone releasing factor for improving mental function

Publications (3)

Publication Number	Publication Date
DK31489D0 DK31489D0 (da)	1989-01-25
DK31489A DK31489A (da)	1989-07-27
DK174866B1 true DK174866B1 (da)	2004-01-05

Family

ID=26846051

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK198900314A DK174866B1 (da)	1988-01-26	1989-01-25	Anvenelse af væksthormonudløsende faktor ved fremstilling af et præparat til diagnose af Alzheimer

Country Status (15)

Country	Link
US (1)	US5089472A (zh)
EP (1)	EP0326381B1 (zh)
JP (2)	JP2847098B2 (zh)
KR (1)	KR970002484B1 (zh)
CN (1)	CN1055641C (zh)
AT (1)	ATE106745T1 (zh)
AU (1)	AU615714B2 (zh)
CA (1)	CA1341017C (zh)
DE (1)	DE68915793T2 (zh)
DK (1)	DK174866B1 (zh)
FI (1)	FI890389A (zh)
IL (1)	IL89056A (zh)
NO (1)	NO890336L (zh)
RU (1)	RU2024261C1 (zh)
UA (1)	UA19804A (zh)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994022469A1 (en) *	1993-04-02	1994-10-13	Ohio University	Enhancement of learning and/or memory by a human somatotropin
JP2010539063A (ja) *	2007-09-11	2010-12-16	モンドバイオテックラボラトリーズアクチエンゲゼルシャフト	Ｇｒｆ−１（１−２９）および副腎皮質刺激ホルモン放出因子の、治療剤としての使用
US9265458B2 (en)	2012-12-04	2016-02-23	Sync-Think, Inc.	Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en)	2013-03-11	2016-07-05	Sync-Think, Inc.	Optical neuroinformatics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8318552D0 (en) *	1983-07-08	1983-08-10	Sandoz Ltd	Organic compounds
US4747825A (en) *	1984-06-29	1988-05-31	Ferring Laboratories, Inc.	Apparatus and methodology for pulsed administration of growth promoting agents
JPH085913B2 (ja) *	1985-09-12	1996-01-24	ザ・アドミニストレ−タ−ズ・オブ・ザ・ツ−レイン・エデユケイシヨナル・フアンド	治療用ソマトスタチン同族体
US4939124A (en) *	1988-01-26	1990-07-03	Laboratorios Serono S.A.	Treatment and diagnosis of dementia

1988
- 1988-06-13 US US07/206,100 patent/US5089472A/en not_active Expired - Lifetime
1989
- 1989-01-23 AU AU28700/89A patent/AU615714B2/en not_active Expired
- 1989-01-24 IL IL8905689A patent/IL89056A/en unknown
- 1989-01-25 RU SU894613597A patent/RU2024261C1/ru active
- 1989-01-25 UA UA4613597A patent/UA19804A/uk unknown
- 1989-01-25 KR KR89000761A patent/KR970002484B1/ko not_active IP Right Cessation
- 1989-01-25 DK DK198900314A patent/DK174866B1/da not_active IP Right Cessation
- 1989-01-25 JP JP1017386A patent/JP2847098B2/ja not_active Expired - Lifetime
- 1989-01-26 AT AT89300751T patent/ATE106745T1/de not_active IP Right Cessation
- 1989-01-26 CN CN89101534A patent/CN1055641C/zh not_active Expired - Lifetime
- 1989-01-26 CA CA000589280A patent/CA1341017C/en not_active Expired - Fee Related
- 1989-01-26 FI FI890389A patent/FI890389A/fi not_active Application Discontinuation
- 1989-01-26 NO NO89890336A patent/NO890336L/no unknown
- 1989-01-26 DE DE68915793T patent/DE68915793T2/de not_active Expired - Lifetime
- 1989-01-26 EP EP89300751A patent/EP0326381B1/en not_active Expired - Lifetime
1998
- 1998-02-16 JP JP10032715A patent/JP2965949B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0326381B1 (en)	1994-06-08
JP2847098B2 (ja)	1999-01-13
AU615714B2 (en)	1991-10-10
FI890389A0 (fi)	1989-01-26
EP0326381A2 (en)	1989-08-02
RU2024261C1 (ru)	1994-12-15
DK31489D0 (da)	1989-01-25
KR970002484B1 (en)	1997-03-05
KR890011572A (ko)	1989-08-21
NO890336L (no)	1989-07-27
AU2870089A (en)	1989-07-27
DE68915793D1 (de)	1994-07-14
EP0326381A3 (en)	1991-08-14
IL89056A (en)	1994-07-31
DE68915793T2 (de)	1995-03-09
IL89056A0 (en)	1989-08-15
JPH0242025A (ja)	1990-02-13
ATE106745T1 (de)	1994-06-15
JPH10251167A (ja)	1998-09-22
DK31489A (da)	1989-07-27
CN1036509A (zh)	1989-10-25
UA19804A (uk)	1997-12-25
CN1055641C (zh)	2000-08-23
US5089472A (en)	1992-02-18
NO890336D0 (no)	1989-01-26
JP2965949B2 (ja)	1999-10-18
FI890389A (fi)	1989-07-27
CA1341017C (en)	2000-06-06

Publication	Publication Date	Title
Davila et al.	1988	Plasma homovanillic acid as a predictor of response to neuroleptics
Peterson et al.	1996	Ethanol‐induced change in cardiac and endogenous opiate function and risk for alcoholism
Strickland et al.	1995	Comparison of lithium ratio between African-American and Caucasian bipolar patients
Doran et al.	1986	CSF somatostatin and abnormal response to dexamethasone administration in schizophrenic and depressed patients
DeNucci et al.	1996	Identifying a neurobiologic basis for drug therapy in TMDs
Garner et al.	1985	Some visual effects caused by the beverage kava
Fountoulakis et al.	2004	Neurobiological and psychological correlates of suicidal attempts and thoughts of death in patients with major depression
Baumgartner et al.	1990	Neuroendocrinological investigations during sleep deprivation in depression I. Early morning levels of thyrotropin, TH, cortisol, prolactin, LH, FSH, estradiol, and testosterone
Banki et al.	1984	Thyroid stimulation test in healthy subjects and psychiatric patients
DK174866B1 (da)	2004-01-05	Anvenelse af væksthormonudløsende faktor ved fremstilling af et præparat til diagnose af Alzheimer
Gottardis et al.	1990	The secretion of human growth hormone stimulated by human growth hormone releasing factor following severe cranio-cerebral trauma
Ericksson et al.	1988	Growth hormone responses to the alpha2-adrenoceptor agonist guanfacine and to growth hormone releasing hormone in depressed patients and controls
Valdés et al.	1989	Psychogenic pain and depressive disorders: an empirical study
Schittecatte et al.	1994	Effect of gender and diagnostic on growth hormone response to clonidine for major depression: A large scale multicenter study
Roy	1988	Cortisol nonsuppression in depression: relationship to clinical variables
US4939124A (en)	1990-07-03	Treatment and diagnosis of dementia
Poehlau et al.	1997	Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis-outline of a double-blind randomized, placebo-controlled trial
Molnar	1983	Seizures associated with high maprotiline serum concentrations
Franceschi et al.	1988	Tuberoinfundibular dopaminergic function in Parkinson’s disease
Atkinson Jr et al.	1983	Neuroendocrine function and endogenous opioid peptide systems in chronic pain
del Campo et al.	2000	Diurnal variations in endocrine and psychological responses to 0.2 mg/kg naloxone administration in patients with major depressive disorder and matched controls
Lu et al.	1986	Correlation between plasma cortisol and CSF catecholamines in endogenous depressed dexamethasone nonsuppressors
Chaney et al.	1980	Cognitive deficit in middle-aged alcoholics
Luijckx et al.	1995	Parkinsonism in alcohol withdrawal: case report and review of the literature
Loosen et al.	1986	The TRH test during dopamine receptor blockade in depressed patients

Legal Events

Date	Code	Title	Description
2009-02-09	PUP	Patent expired